Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
Sun Pharmaceutical Industries has agreed to supply its innovative medicines to U.S. Medicaid programs at Most Favoured Nation (MFN) pricing. This commitment follows a White House ceremony where the U.S. government signed agreements with nine pharmaceutical companies, including Sun Pharma, to improve access to affordable medicines for millions of Americans.
The MFN pricing agreement recognizes Sun Pharma's significant investment in the U.S. market, as the company delays Section 232 tariffs on innovative pharmaceutical products for over two years. The U.S. is Sun Pharma's largest market for innovative medicines, accounting for approximately 27% of the company's global revenue. Sun Pharma's CEO, Rick Ascroft, emphasized the company's commitment to delivering essential medicines to American patients.
The MFN pricing agreement will provide every state Medicaid program in the U.S. access to MFN drug prices, potentially resulting in billions of dollars in savings for Americans.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
